HER2 Gene Mutation Clinical Trial
Official title:
An Open-label, Single-arm, Multicenter, Phase II Clinical Study of Disitamab Vedotin Plus Cadonilimab as Therapy in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
It is a single arm, open-label, phase II cinical trial to evaluate the efficacy and safety of Disitamab Vedotin Plus Cadonilimab in second-line treatment of patients with Advanced or Metastatic Bile Duct Adenocarcinoma
Biliary tract cancer is a group of highly heterogeneous and aggressive epithelial cancers, accounting for about 3% of all digestive system tumors. It is highly aggressive, and most of them are found in advanced stages, with extremely poor prognosis and a 5-year survival rate of less than 5%. The overexpression rate of HER2 in biliary tract tumors is about 26.5%, and the amplification rate is about 30.1%. In addition, HER2 mutations in biliary tract malignant tumors also include HER2 mutations. In addition, HER2 mutations in biliary malignant tumors also include HER2 mutations. Currently, anti-HER2 strategies have become a new hotspot for exploration in BTC. It is a single arm, open-label, phase II cinical trial conducted in China and plans to recruit 28 patients with HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma who have progressed through first-line treatment. The purpose of this study is to evaluate the efficacy and safety of second-line treatment with Disitamab Vedotin Plus Cadonilimab ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05511844 -
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02979821 -
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
|
Phase 2 | |
| Completed |
NCT03845270 -
Her2-positive Lung Cancer Treated With Dedicated Drug
|
Phase 2 | |
| Recruiting |
NCT05673512 -
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05650879 -
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06282575 -
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT06083662 -
Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers
|
Phase 2 | |
| Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03743350 -
NSCLC Exon 20 or HER2-activating Mutations
|
Phase 2 | |
| Recruiting |
NCT03412383 -
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06123338 -
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04620187 -
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
|
Phase 2 | |
| Not yet recruiting |
NCT04179656 -
The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
|
Phase 2 | |
| Recruiting |
NCT05991518 -
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06178445 -
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT06449989 -
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
|